Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Epithelial cell states distinguish between uterine cancers
Fri December 3rd - Two epithelial cell states have been identified that can help to distinguish between types of uterine cancer, British researchers announced last night. More
COVID-19 boosters increase immunity
Fri December 3rd - Six different types of COVID-19 boosters are safe and increase immunity following vaccination with either the AstraZeneca or Pfizer-BioNTech jabs, British researchers report today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Inhaled treatment could help severe COVID disease

Friday November 13th 2020

An inhaled immune system protein, developed for asthma, can help patients with severe COVID-19 disease, British researchers have reported.

The study of interferon beta-1a involved 101 patients in Southampton.

Researchers report that use of the inhaled treatment doubled the chance of patients recovered to the extent of being able to resume everyday activities.

The findings were reported in The Lancet Respiratory Medicine.

They show that 11 out of 50 patients receiving placebo developed severe disease compared with six of the 48 patients receiving the interferon treatment. There was a similar difference in recovery rates over 14 days – 21 of those receiving treatment compared with 11 of those on placebo.

Researcher Professor Tom Wilkinson, from Southampton University, said: The results confirm our belief that interferon beta, a widely known drug approved for use in its injectable form for other indications, may have the potential as an inhaled drug to restore the lung's immune response and accelerate recovery from COVID-19. Inhaled interferon beta-1a provides high, local concentrations of the immune protein, which boosts lung defences rather than targeting specific viral mechanisms.

“This might carry additional advantages of treating COVID-19 infection when it occurs alongside infection by another respiratory virus, such as influenza or respiratory syncytial virus that may well be encountered in the winter months."

The journal reports that a trial of injected interferon has not demonstrated efficacy – but that the inhaled treatment may ensure delivery to the lungs.

Writing in the journal Nathan Peiffer-Smadja, from Assistance Publique - Hôpitaux de Paris, France, says: "The number of patients enrolled in this pilot clinical trial is of course small. In addition, this study neither showed any impact of the evaluated treatment on time to discharge nor on mortality, although the study was obviously not powered to respond to the latter question. Larger randomised clinical trials are therefore needed to confirm these results.

“The safety of nebulised interferon beta-1a will be of special interest since nebulisation of interferon has no marketing authorisation for any indication yet.”

Lancet Respiratory Medicine 12 November 2020


Tags: Flu & Viruses | Pharmaceuticals | Respiratory | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)